Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Robert W. Baird from $119.00 to $123.00. They now have an "outperform" rating on t

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com